2023-11-15T12:16:46-06:00 2022-12-31 954649521 MELONI HRIBAL TRATNER LLP 21600 OXNARD STREET 500 WOODLAND HILLS CA 91367 990 2022-01-01 473169795 THE FAMILIESCN2A FOUNDATION INC FAMI 3012528070 PO BOX 4260 GETTYSBURG PA 17325 JENNIFER BURKE TREASURER 3012528070 2023-11-14 1 JENNIFER BURKE 999009999 0 REBECCA Y SO P00535828 8185873730 2023-11-14 2 AAL1 IAL1 2022 2023-04-26 12:10:37Z JENNIFER BURKE PO BOX 4260 GETTYSBURG PA 17325 1486870 0 X WWW.SCN2A.ORG X 2015 MA THE FAMILIESCN2A IS DEDICATED TO FINDING EFFECTIVE TREATMENTS AND ULTIMATELY A CURE FOR SCN2A RELATED AUTISM AND EPILEPSY DISORDERS. THE FAMILIESCN2A FOUNDATION RAISES PUBLIC AWARENESS, PROVIDES PATIENT ADVOCACY, AND SUPPORTS CLINICAL RESEARCH, GENETIC RESEARCH, AND EARLY DETECTION. 9 9 3 10 0 0 843741 1414320 0 72550 0 0 0 0 843741 1486870 291461 298568 0 0 95378 132433 0 0 58956 91952 559761 478791 990762 364950 496108 1231993 1757650 95292 124841 1136701 1632809 THE FAMILIESCN2A'S MISSION IS TO IMPROVE LIVES OF THOSE AFFECTED BY SCN2A RELATED DISORDERS THROUGH RESEARCH, PUBLIC AWARENESS, FAMILY SUPPORT AND PATIENT ADVOCACY. 0 0 734539 298568 PROVIDING ADVANCED RESEARCH TOWARDS EARLY DETECTION, TREATMENTS AND A CURE FOR SCN2A DISORDERS. 120775 72550 THE SUMMER SEMINAR IS A FAMILY-FOCUSED GATHERING, WHERE FAMILIES COME TOGETHER AND LEARN ABOUT SCN2A-RELATED TOPICS AND TREATMENTS, AS WELL AS SHARE EXPERIENCES. 855314 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 3 0 1 3 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 X 9 9 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 MA CA X X FORTISS LLC 3234154917 1100 S FLOWER ST STE 3100 LOS ANGELES CA 90015 LEAH SCHUST MYERS EXECUTIVE DIRECTOR 60.00 X 90000 0 0 CATALINA BETANCUR SANTAMARIA DIRECTOR 2.00 X 0 0 0 WILL HUTSON DIRECTOR 2.00 X 0 0 0 MAURA BRAGG DIRECTOR 2.00 X 0 0 0 EMILY PARK DIRECTOR 5.00 X 0 0 0 MERY OMAN VICE PRESIDENT 2.00 X 0 0 0 ROGER PREMO DIRECTOR 2.00 X 0 0 0 SHAWN EGAN CHIEF SCIENTIFIC OFFICER 20.00 X 4327 0 0 CARLA FORBES ADMINISTRATIVE MANAGER 20.00 X 18745 0 0 JENNIFER BURKE PRESIDENT 5.00 X 0 0 0 MICHELLE LEWIS SECRETARY 5.00 X 0 0 0 MICHAEL VASEY TREASURER 5.00 X 0 0 0 113072 0 0 0 0 0 0 0 1414320 30198 1414320 SCN2A SUMMER CONFERENC 611710 72550 72550 72550 1486870 72550 0 0 X 298568 298568 113072 84804 5653 22615 19361 14521 968 3872 33883 33883 544 544 8197 4099 2049 2049 20047 13107 6940 26774 13387 13387 120775 120775 1193 1193 RESEARCH AND DEVELOPMEN 281920 281920 CONSULTING EXPENSE 24369 24369 STRATEGIC PLANNING 12082 12082 MERCHANDISE EXPENSE 6375 6375 23602 12871 5708 5023 990762 855314 76492 58956 871766 1196720 359011 557369 1216 3561 1231993 1757650 95292 124841 95292 124841 X 923010 1190725 213691 442084 1136701 1632809 1231993 1757650 496108 0 X X 0 1 X 1 0 X 147256 859862 605287 808341 1486870 3907616 147256 859862 605287 808341 1486870 3907616 2131573 1776043 3907616 0.45450 0.49460 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 1486870 0 1486870 0 1486870 990762 0 990762 0 990762 1 SOUTH AMERICA 0 0 GRANT TO RECIPIENTS LOCATED IN REGION 23518 0 0 0 0 0 0 23518 0 23518 SOUTH AMERICA TO SUPPORT ADVANCED RESEARCH TOWARDS TREATMENTS AND CURE FOR SCN2A DISORDERS. 23518 WIRE TRASNFER 0 1 0 0 0 0 0 0 PART I, LINE 2: A WRITTEN SCIENTIFIC PROGRESS REPORT REGARDING THE PROJECT MUST BE SUBMITTED TO THE FOUNDATION SIX (6) MONTHS FROM THE EFFECTIVE DATE FOR THE RELEASE OF FUNDING AS DESCRIBED IN THE GRANT AGREEMENT. A FINAL SCIENTIFIC PROGRESS REPORT AND FINANCIAL REPORT DETAILING ALL EXPENDITURES FOR THE LIFE OF THE GRANT WILL BE DUE NO LATER THAN SIXTY (60) DAYS FOLLOWING THE EXPIRATION OR TERMINATION OF THE GRANT AS DESCRIBED IN THE FOUNDATION'S POLICY STATEMENT ON RESEARCH SUPPORT. IN ADDITION, ANNUAL FINANCIAL REPORTS ARE SUBMITTED TO THE FOUNDATION TO SUBSTANTIATE EXPENSES FOR THE APPLICABLE PERIOD. PART I, LINE 3: THE ACCRUAL ACCOUNTING METHOD IS USED TO ACCOUNT FOR EXPENDITURES. ANNUAL FINANCIAL REPORTS ARE SUBMITTED TO SUBSTANTIATE EXPENSES FOR THE APPLICABLE PERIOD. ONCE EXPENSES ARE SUBSTANTIATED, A REFUNDABLE ADVANCE IS DETERMINED IF ADVANCES MADE DURING THE CALENDAR YEAR EXCEED EXPENSES INCLUDED IN THE ANNUAL FINANCIAL REPORT. PART III ACCOUNTING METHOD: 1 ANN & ROBERT H LURIE CHILDREN'S HOSPITAL OF CHICAGO 225 E CHICAGO AVE CHICAGO IL 606112605 362170833 12433 0 TO SUPPORT ADVANCED RESEARCH TOWARDS TREATMENTS AND CURE FOR SCN2A DISORDERS. UNIVERSITY OF ALABAMA BOX 870348 TUSCALOOSA AL 35487 636001138 10939 0 TO SUPPORT ADVANCED RESEARCH TOWARDS TREATMENTS AND CURE FOR SCN2A DISORDERS. PURDUE UNIVERSITY 207 S MARTIN JISCHKE DRIVE WEST LAFAYETTE IN 47907 356002041 46419 0 TO SUPPORT ADVANCED RESEARCH TOWARDS TREATMENTS AND CURE FOR SCN2A DISORDERS. UNIVERSITY OF IOWA 201 S CLINTON ST IOWA CITY IA 522424034 426004813 46175 0 TO SUPPORT ADVANCED RESEARCH TOWARDS TREATMENTS AND CURE FOR SCN2A DISORDERS. UNIVERSITY OF CALIFORNIA DAVIS PO BOX 741816 LOS ANGELES CA 90074 946036494 52625 0 TO SUPPORT ADVANCED RESEARCH TOWARDS TREATMENTS AND CURE FOR SCN2A DISORDERS. COMBINEDBRAIN 1510 OLD HICKORY BLVD BRENTWOOD TN 37027 831825692 61405 0 TO SUPPORT ADVANCED RESEARCH TOWARDS TREATMENTS AND CURE FOR SCN2A DISORDERS. TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 3535 MARKET STREET SUITE 750 PHILADELPHIA PA 19104 231352685 23003 0 TO SUPPORT ADVANCED RESEARCH TOWARDS TREATMENTS AND CURE FOR SCN2A DISORDERS. GLADSTONE INSTITUTES 1650 OWENS STREET SAN FRANCISCO CA 94158 237203666 22051 0 TO SUPPORT ADVANCED RESEARCH TOWARDS TREATMENTS AND CURE FOR SCN2A DISORDERS. 8 X 161 30198 FAIR MARKET VALUE 0 1 1 PART I, LINE 32B: THE ORGANIZATION USED TD AMERITRADE TO SELL STOCK DONATIONS. FORM 990, PART VI, SECTION A, LINE 2 EMILY PARK (DIRECTOR) AND MICHAEL VASEY (TREASURER) HAVE A BUSINESS RELATIONSHIP. FORM 990, PART VI, SECTION B, LINE 11B THE RETURN IS FURNISHED TO THE ORGANIZATION'S TREASURER FOR REVIEW AND SUBMITTED TO EXECUTIVE BOARD (EXECUTIVE DIRECTOR, PRESIDENT, VICE PRESIDENT, TREASURER AND SECRETARY) FOR APPROVAL BEFORE THE RETURN IS SUBMITTED FOR FILING. FORM 990, PART VI, SECTION B, LINE 12C ANY INTERESTS THAT COULD GIVE RISE TO CONFLICT MUST BE DISCLOSED TO THE BOARD. HOWEVER, NO CONTRACT OR TRANSACTION BETWEEN THE ORGANIZATION AND ONE OR MORE OF ITS MEMBERS, DIRECTORS OR OFFICERS OR ANY OTHER FOUNDATION, PARTNERSHIP, ASSOCIATION, OR OTHER ORGANIZATION IN WHICH ONE OR MORE OF THIS FOUNDATION'S DIRECTORS OR OFFICERS ARE DIRECTORS OR OFFICERS, OR HAVE A FINANCIAL INTEREST, SHALL BE VOID OR VOIDABLE SOLELY FOR SUCH REASON, OR SOLELY BECAUSE THE MEMBER, DIRECTOR OR OFFICER IS PRESENT AT OR PARTICIPATES IN THE MEETING OF THE BOARD OF DIRECTORS WHICH AUTHORIZES THE CONTRACT OR TRANSACTION, OR SOLELY BECAUSE HIS OR THEIR VOTES ARE COUNTED FOR SUCH PURPOSE, IF: A. THE MATERIAL FACTS AS TO THE RELATIONSHIP OR INTEREST AND AS TO THE CONTRACT OR TRANSACTION ARE DISCLOSED OR ARE KNOWN TO THE BOARD OF DIRECTORS AND THE BOARD OF DIRECTORS IN GOOD FAITH AUTHORIZES THE CONTRACT OR TRANSACTION BY THE AFFIRMATIVE VOTES OF A MAJORITY OF THE DISINTERESTED DIRECTORS EVEN THOUGH THE DISINTERESTED DIRECTORS ARE LESS THAN A QUORUM; B. THE MATERIAL FACTS AS TO HIS RELATIONSHIP OR INTEREST AND AS TO THE CONTRACT OR TRANSACTION ARE DISCLOSED OR ARE KNOWN TO THE BOARD OF DIRECTORS, AND THE CONTRACT OR TRANSACTION IS SPECIFICALLY APPROVED IN GOOD FAITH BY VOTE OF SUCH DIRECTORS; OR C. THE CONTRACT OR TRANSACTION IS FAIR AS TO THE ORGANIZATION AS OF THE TIME IT IS AUTHORIZED, APPROVED OR RATIFIED BY THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION B, LINE 15A THE COMPENSATION COMMITTEE SHALL CONSIST OF THE PRESIDENT AND VICE PRESIDENT. THEY WILL REVIEW THE SALARY AND OTHER BENEFITS OF THE EXECUTIVE DIRECTOR. AS PART OF THIS REVIEW, THE COMPENSATION COMMITTEE WILL MAKE A RECOMMENDATION TO THE BOARD OF DIRECTORS REGARDING THE EXECUTIVE DIRECTOR'S SALARY AND OTHER BENEFITS TO BE PAID FOR THE UPCOMING YEAR. THIS SHALL BE DONE ON AN ANNUAL BASIS. THE VOTE OF A MAJORITY OF THE DIRECTORS ENTITLED TO VOTE AT A MEETING AT WHICH THERE IS A QUORUM SHALL DETERMINE THE SALARY AND OTHER BENEFITS OF THE EXECUTIVE DIRECTOR AND THIS SHALL BE DONE ON AN ANNUAL BASIS, NO LATER THAN SIXTY (60) DAYS AFTER THE ANNIVERSARY DATE OF THE EXECUTIVE DIRECTOR'S DATE OF HIRE. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MADE ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON ITS OWN WEBSITE AND GUIDE STAR UPON REQUEST. FORM 990, PART IX, LINE 24E RESEARCH PARTICIPANT INCENTIVES: PROGRAM SERVICE EXPENSES 5,400. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 5,400. BANK CHARGES/CREDIT CARD FEES: PROGRAM SERVICE EXPENSES 722. MANAGEMENT AND GENERAL EXPENSES 241. FUNDRAISING EXPENSES 3,853. TOTAL EXPENSES 4,816. SUPPLIES AND MATERIALS: PROGRAM SERVICE EXPENSES 170. MANAGEMENT AND GENERAL EXPENSES 3,211. FUNDRAISING EXPENSES 862. TOTAL EXPENSES 4,243. POSTAGE AND SHIPPING: PROGRAM SERVICE EXPENSES 1,874. MANAGEMENT AND GENERAL EXPENSES 1,874. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 3,748. PATIENT ASSISTANCE PROGRAM: PROGRAM SERVICE EXPENSES 1,500. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 1,500. MEMBERSHIPS AND DUES: PROGRAM SERVICE EXPENSES 1,084. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 1,084. PRINTING AND COPYING: PROGRAM SERVICE EXPENSES 273. MANAGEMENT AND GENERAL EXPENSES 170. FUNDRAISING EXPENSES 308. TOTAL EXPENSES 751. FAMILY EVENT PROGRAM: PROGRAM SERVICE EXPENSES 618. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 618. BIRTHDAY PROGRAM : PROGRAM SERVICE EXPENSES 543. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 543. STAFF DEVELOPMENT: PROGRAM SERVICE EXPENSES 212. MANAGEMENT AND GENERAL EXPENSES 212. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 424. MEMORIAL WINDCHIME PROGRAM: PROGRAM SERVICE EXPENSES 289. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 289. HOSPITAL GIFTS PROGRAM: PROGRAM SERVICE EXPENSES 186. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 186. FORM 990, PART XII, LINE 2C PROCESS DID NOT CHANGE FROM PRIOR YEAR.